Clinical Trial Update: Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients. [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetic/pharmacodynamic study of epoetin alfa (Procrit) in critically ill patients with anemia. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Critical Illness

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, Critical Illness | Phase 2 | Status: COMPLETED